59908-47-3Relevant articles and documents
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis
Arnhof, Heribert,Bader, Gerd,Bruchhaus, Jens,Burkard, Michelle,Ciftci, Tuncay,Dahmann, Georg,Du, Alicia,Ettmayer, Peter,Fett, Thomas N.,Garavel, Géraldine,Gerstberger, Thomas,Haering, Daniela,Harrer, Christoph,Hofbauer, Karin S.,Kessler, Dirk,Kousek, Roland,Li, Dongyang,Li, Yali,Lv, Xiaobing,Martinelli, Paola,Mayer, Moriz,McConnell, Darryl B.,Mischerikow, Nikolai,Mitzner, Sophie,Pearson, Mark,Peric-Simov, Biljana,Quant, Jens,Rinnenthal, Joerg,Rumpel, Klaus,Savarese, Fabio,Scherbantin, Yvonne,Schnitzer, Renate,Scholz, Guido,Schrenk, Andreas,Sharps, Bernadette,Sommergruber, Wolfgang,Treu, Matthias,Weinstabl, Harald,Wolkerstorfer, Bernhard,Zahn, Stephan K.,Zhang, Xuechun,Zoephel, Andreas
, (2019/09/06)
Phosphoglycerate dehydrogenase (PHGDH) is known to be the rate-limiting enzyme in the serine synthesis pathway in humans. It converts glycolysis-derived 3-phosphoglycerate to 3-phosphopyruvate in a co-factor-dependent oxidation reaction. Herein, we report the discovery of BI-4916, a prodrug of the co-factor nicotinamide adenine dinucleotide (NADH/NAD+)-competitive PHGDH inhibitor BI-4924, which has shown high selectivity against the majority of other dehydrogenase targets. Starting with a fragment-based screening, a subsequent hit optimization using structure-based drug design was conducted to deliver a single-digit nanomolar lead series and to improve potency by 6 orders of magnitude. To this end, an intracellular ester cleavage mechanism of the ester prodrug was utilized to achieve intracellular enrichment of the actual carboxylic acid based drug and thus overcome high cytosolic levels of the competitive cofactors NADH/NAD+
Flexibility of small molecular CD4 mimics as HIV entry inhibitors
Kobayakawa, Takuya,Ohashi, Nami,Hirota, Yuki,Takahashi, Kohei,Yamada, Yuko,Narumi, Tetsuo,Yoshimura, Kazuhisa,Matsushita, Shuzo,Harada, Shigeyoshi,Tamamura, Hirokazu
supporting information, p. 5664 - 5671 (2018/10/24)
CD4 mimics such as YIR-821 and its derivatives are small molecules which inhibit the interaction between the Phe43 cavity of HIV-1 gp120 with host CD4, an interaction that is involved in the entry of HIV to cells. Known CD4 mimics generally possess three
N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient
-
, (2017/05/18)
The present invention relates to N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, a preparation method thereof, and a pharmaceutical composition for preventing or treating urotensin-II receptor activity-related diseases comprising the same as activ